[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"perioperative-bleeding\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:perioperative-bleeding":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,83,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100054134","appropriateness-of-hemostatic-agent-use-in-cardiovascular-surgery-haemovax-100054134",false,"NCT07699016","Appropriateness of Hemostatic Agent Use in Cardiovascular Surgery (HAEMOVAX)","Evaluation of Appropriateness in the Use of Hemostatic Agents in Cardiovascular Surgery: A Mixed-Methods Single-Center Observational Study","HAEMOVAX","Inclusion Criteria:\n\n* Physicians with a surgical role in the Departments of Cardiac Surgery or Vascular Surgery at IRCCS Galeazzi-Sant'Ambrogio, Milan Including attending surgeons, consultant surgeons, and surgical residents\n* Active participation in cardiovascular operative procedures during the study period (or within the preceding 12 months)\n* Employment at the study institution at the time of survey administration Willingness to participate and complete the anonymous structured questionnaire\n\nExclusion Criteria:\n\n* Non-surgical healthcare personnel (e.g., nurses, anesthesiologists, administrative staff, or allied health professionals)\n* Surgeons not involved in operative cardiovascular practice during the study period\n* External collaborators or visiting surgeons without regular clinical activity at the institution\n* Individuals who do not provide informed consent for participation in the anonymous survey\n* Questionnaires with missing or incomplete vignette responses preventing calculation of the KPA-Score",true,"ALL","18 Years",{"count":21,"type":22},15,"ESTIMATED","OBSERVATIONAL","Hemostatic agents are widely used in cardiac and vascular surgery to support intraoperative bleeding control. Despite their clinical relevance and substantial economic impact, little is known about real-world patterns of use, adherence to evidence-based recommendations, and the alignment between clinicians' perceived knowledge and actual decision-making.\n\nHAEMOVAX is a single-center mixed-methods observational study conducted at IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan, Italy. The study combines an anonymous survey of cardiovascular surgeons with a retrospective audit of institutional hemostatic agent consumption. The primary objective is to evaluate the appropriateness of hemostatic agent selection using a Knowledge-Practice Alignment Score (KPA-Score) derived from standardized clinical vignettes based on current EACTS and ESA recommendations. Secondary objectives include assessment of usage patterns, barriers to appropriate use, concordance between declared practice and real-world consumption, and opportunities for evidence-based standardization.",[26,27,28,29,30],"Hemostasis","Perioperative Bleeding","Cardiovascular Surgery","Cardiac Surgery","Vascular Surgery",[32,33,34,27],"Hemostatic Agents","Surgical Hemostasis","Topical Hemostatic Agents","RECRUITING","2026-07-07",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":22},"2026-07-01",{"date":43,"type":22},"2026-08-15",{"name":45,"class":46},"University of Milan","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":23,"phases":4,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100643230","flow-based-platelet-function-assessment-using-total-thrombus-formation-analysis-system-t-tas-and-early-bleeding-after-cardiac-surgery-with-cardiopulmonary-bypass-cpb-100643230","NCT07619261","Flow-Based Platelet Function Assessment Using Total Thrombus-Formation Analysis System (T-TAS) and Early Bleeding After Cardiac Surgery With Cardiopulmonary Bypass (CPB)","Prospective Observational Study of Flow-Based Platelet Function Using T-TAS and Early Bleeding After Cardiopulmonary Bypass in Adult Cardiac Surgery","TTAS-CPB","Inclusion Criteria:\n\n1. Adults aged 18 years or older\n2. Undergoing elective or urgent cardiac surgery requiring cardiopulmonary bypass\n3. Ability to provide written informed consent\n\nExclusion Criteria:\n\n1. Cardiac surgery performed without cardiopulmonary bypass\n2. Emergency cardiac surgery\n3. Preoperative anticoagulation not reversed at the time of surgery\n4. Refusal or withdrawal of informed consent\n5. Known pregnancy",{"count":57,"type":22},30,"2 Days","The goal of this observational study is to learn how flow-based platelet function measured with the Total Thrombus-formation Analysis System (T-TAS) relates to early postoperative bleeding in adults undergoing cardiac surgery with cardiopulmonary bypass. The study will also evaluate how T-TAS changes during the perioperative period and how it compares with standard coagulation and platelet function tests.\n\nThe main questions it aims to answer are:\n\nIs lower post-cardiopulmonary bypass T-TAS Platelet-chip (PL-chip) thrombus formation associated with increased postoperative chest tube drainage during the first 12 hours after surgery? How do T-TAS parameters change before surgery, immediately after cardiopulmonary bypass, and 24 hours after surgery? Are abnormal T-TAS results associated with blood transfusion requirements, major bleeding, re-exploration for bleeding, and length of stay in the intensive care unit and hospital? Does T-TAS provide complementary information compared with standard coagulation tests, von Willebrand factor (vWF) measurements, platelet aggregometry, and viscoelastic testing?\n\nParticipants will:\n\nUndergo blood sampling at three predefined perioperative time points:\n\nbefore anesthesia induction, immediately after cardiopulmonary bypass and heparin reversal with protamine, and 24 hours after surgery Have T-TAS testing, standard laboratory coagulation tests, vWF testing, platelet aggregometry, and viscoelastic testing performed on collected samples Have clinical, surgical, transfusion, and postoperative bleeding data collected during their hospital stay\n\nThe study is observational and does not require changes to routine clinical care or perioperative management.",[27,61,62,29,63],"Coagulopathy During Cardiac Surgery","Platelet Dysfunction","Acquired Von Willebrand Disease",[29,65,66,67,26,68,69,70,71,72],"Total Thrombus formation Analysis System (T-TAS)","Platelet Function","Postoperative Bleeding","Blood Transfusion","ROTEM","Thrombus Formation","Cardiopulmonary Bypass (CPB)","von Willebrand Factor (vWF)","NOT_YET_RECRUITING","2026-06-08",{"date":76,"type":39},"2026-06-10",{"date":78,"type":22},"2026-09-15",{"date":80,"type":22},"2027-02-15",{"name":82,"class":46},"Hospital de la Santa creu i Sant Pau - Barcelona",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":102,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":47},"100637597","stepwise-vs-standard-anticoagulation-for-af-patients-undergoing-cied-implantation-step-af-100637597","NCT07616414","Stepwise vs Standard Anticoagulation for AF Patients Undergoing CIED Implantation (STEP-AF)","Stepwise Versus Standard Antithrombotic Strategies in Patients With Atrial Fibrillation at High Thromboembolic Risk Undergoing CIED Procedures (STEP-AF Trial)","STEP-AF","Inclusion Criteria:\n\n1. Aged 18 years or older at the time of screening, and able to provide written informed consent;\n2. Scheduled for any CIED procedure (implantation or generator replacement), including pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices;\n3. Receiving NOAC therapy for at least 5 consecutive days prior to enrollment;\n4. Diagnosed with non-valvular atrial fibrillation (and\u002For atrial flutter) with a CHA₂DS₂-VASc score ≥2, or scheduled for cardioversion or defibrillation threshold testing during the CIED procedure.\n\nExclusion Criteria:\n\n1. Presence of active systemic or local infection at the time of screening;\n2. Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin, or any other contraindication to NOAC use;\n3. Active bleeding (e.g., gastrointestinal bleeding);\n4. Severe thrombocytopenia, defined as platelet count \\\u003C 50 × 10⁹\u002FL at screening;\n5. Life expectancy \\\u003C1 year;\n6. Pregnancy.",{"count":92,"type":22},424,"INTERVENTIONAL",[95],"NA","This is a multi-center, prospective, open-label, randomized controlled trial (STEP-AF) designed to evaluate the safety of a stepwise anticoagulation strategy compared with the guideline-recommended standard anticoagulation regimen in patients with non-valvular atrial fibrillation at high thromboembolic risk (CHA₂DS₂-VASc score ≥2) undergoing cardiac implantable electronic device (CIED) implantation. A total of 424 eligible patients will be randomized 1:1 to either the stepwise anticoagulation group (reduced-dose NOAC from 24 hours post-surgery to day 7, followed by standard-dose NOAC) or the standard anticoagulation group (standard-dose NOAC resumed 24 hours post-surgery). The primary endpoint is the incidence of clinically significant pocket hematoma within 30 days after surgery. Secondary endpoints include individual components of the primary endpoint and other composite outcomes of major perioperative bleeding events. The study aims to provide evidence-based data for optimizing perioperative anticoagulation regimens in Chinese patients undergoing CIED implantation.",[98,99,100,27,101],"Non-valvular Atrial Fibrillation (NVAF)","Thromboembolism","Cardiac Implantable Electronic Device","Hematoma Postoperative",[103,100,104,105,106,107,108,109,99,27,110,111,112],"Non-valvular atrial fibrillation","CIED","Perioperative Anticoagulation","Non-Vitamin K Antagonist Oral Anticoagulant","NOAC","Stepwise Anticoagulation","Postoperative hematoma","Randomized Controlled Trial","Edoxaban","Rivaroxaban","2026-05-23",{"date":115,"type":39},"2026-06-01",{"date":117,"type":22},"2026-05-26",{"date":119,"type":22},"2026-12-31",{"name":121,"class":46},"Fu Wai Hospital, Beijing, China",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":130,"minAge":131,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":93,"phases":134,"briefSummary":136,"conditions":137,"keywords":141,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":47},"100628352","phase-4-tranexamic-acid-for-bleeding-reduction-during-turp-surgery-100628352","NCT07460518","Tranexamic Acid for Bleeding Reduction During TURP Surgery","Tranexamic Acid for Perioperative Haemostatic Optimisation During Transurethral Resection of the Prostate: A Randomized Quadruple-Blind Placebo-Controlled Trial","TXA-TURP","Inclusion Criteria:\n\n* Male patients aged 50 years or older\n* Diagnosed with benign prostatic hyperplasia (BPH)\n* Scheduled for elective transurethral resection of the prostate (TURP) under spinal anesthesia\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Provided written informed consent\n\nExclusion Criteria:\n\n* History of thromboembolic disease (deep vein thrombosis, pulmonary embolism, stroke)\n* Known hypersensitivity to tranexamic acid\n* Severe renal impairment (creatinine clearance \\\u003C30 mL\u002Fmin)\n* Coagulation disorders\n* Current anticoagulant therapy not appropriately discontinued\n* History of seizure disorder\n* Refusal to participate","MALE","50 Years",{"count":133,"type":22},80,[135],"PHASE4","Transurethral resection of the prostate (TURP) is commonly performed in elderly patients and may be associated with perioperative bleeding leading to postoperative anemia and delayed recovery. Tranexamic acid (TXA), an antifibrinolytic agent, may reduce surgical bleeding by inhibiting fibrin degradation.\n\nThis prospective randomized quadruple-blind placebo-controlled clinical trial evaluates whether perioperative administration of intravenous tranexamic acid reduces intraoperative blood loss and preserves postoperative hemoglobin concentration in patients undergoing TURP under standardized spinal anesthesia.\n\nParticipants are randomly assigned to receive either intravenous tranexamic acid or placebo prior to surgery. The primary outcomes assess objective measures of perioperative blood loss and postoperative hemoglobin levels. Secondary outcomes include recovery parameters, perioperative safety, and exploratory hospital-level economic impact.\n\nThe study aims to determine whether anesthesia-led haemostatic optimization using tranexamic acid improves perioperative physiological stability and recovery efficiency within an enhanced recovery framework.",[138,139,27,140],"Benign Prostatic Hyperplasia","Transurethral Resection of the Prostate","Anemia, Postoperative",[142,143,144,145,110,26,146,147],"Tranexamic Acid","TURP","Patient Blood Management","Spinal Anesthesia","Enhanced Recovery After Surgery","Perioperative Medicine","2026-03-05",{"date":150,"type":39},"2026-03-10",{"date":152,"type":22},"2026-03-15",{"date":154,"type":22},"2026-09-01",{"name":156,"class":46},"Hamza Najout"]